$REGN Recent News Nasdaq falls for 4th day in ro
Post# of 89322
Posted On: 03/14/2014 12:52:43 PM
$REGN Recent News
Nasdaq falls for 4th day in row; Dow, S&P slip for 2nd day: stock market live blog recap 3:51 p.m. March 11, 2014 - blogs.marketwatch.com
Bull market’s biggest winners and losers 7:00 a.m. March 10, 2014 - Jeff Reeves
Lorillard and Reynolds jump on buyout report 5:16 p.m. March 3, 2014 - Sue Chang
Sprint gains on narrower loss; WPX tops S&P 500 losers 5:15 p.m. Feb. 11, 2014 - Sue Chang
Dow nabs best gain of year after Yellen remarks, debt-ceiling news: stock market live blog recap 4:55 p.m. Feb. 11, 2014 - blogs.marketwatch.com
Regeneron diabetic eye remedy does well in trial 9:02 a.m. Feb. 10, 2014 - MarketWatch.com
Stocks stabilize; now it’s up to Yellen, the consumer 9:01 a.m. Feb. 9, 2014 - Wallace Witkowski
Tesla extends gains; ExOne sinks on revenue warning 4:45 p.m. Jan. 15, 2014 - Sue Chang
GameStop tumbles 20%; Tesla surges on strong sales 5:23 p.m. Jan. 14, 2014 - Sue Chang
Regeneron climbs by double-digits, leads S&P after presentation 4:58 p.m. Jan. 14, 2014 - Russ Britt
Dow jumps 116 points, best day this year: Stock market live blog recap 4:51 p.m. Jan. 14, 2014 - blogs.marketwatch.com
Three biopharma companies poised for product OKs in 2014: analyst 1:51 p.m. Jan. 6, 2014 - Russ Britt
Goldman's biotech downgrade and the new consensus 12:53 p.m. Jan. 6, 2014 - MarketWatch.com
Apple off on market data, Twitter down as options debut 5:36 p.m. Nov. 15, 2013 - Sue Chang
Macy's, Potbelly gain; Chegg slumps in debut 6:04 p.m. Nov. 13, 2013 - Sue Chang
GT spikes on sapphire deal with Apple 5:45 p.m. Nov. 5, 2013 - Sue Chang
Regeneron shares near $300 as earnings report emboldens investors 12:14 p.m. Nov. 5, 2013 - Russ Britt
The next big pharma 7:01 a.m. Oct. 25, 2013 - The Trading Deck
Apple extends gains on price target hike 3:47 p.m. Oct. 16, 2013 - Sue Chang
Apple gains on upgrade; BlackBerry rallies 4:34 p.m. Oct. 7, 2013 - Sue Chang
Piper Jaffray Stocks to Buy for S&P 500 Going to 2,100 8:00 a.m. March 13, 2014 - 247WallSt.com
Biotech Stock Roundup: Amgen, Regeneron Slide on PCSK9 Inhibitor Concerns - Analyst Blog 10:50 a.m. March 12, 2014 - Zacks.com
Next Stop for the Nasdaq: 5000 3:33 a.m. March 8, 2014 - Barrons.com
Jim Cramer's 'Mad Money' Recap: Next Week's Game Plan 8:17 p.m. March 7, 2014 - TheStreet.com
FDA Advises of Adverse Effects from New Cholesterol Drugs 6:08 p.m. March 7, 2014 - The Wall Street Journal Interactive Edition
Regeneron and Sanofi to look into side effects of cholesterol drug candidate 4:24 p.m. March 7, 2014 - Seeking Alpha
3 Stocks Reiterated As A Hold: FCX, TSLA, REGN 3:01 p.m. March 7, 2014 - TheStreet.com
Water-Logged And Getting Wetter: Regeneron Pharmaceuticals (REGN) 1:17 p.m. March 7, 2014 - TheStreet.com
Regeneron Cholesterol-Drug Worries Ding Stock 1:11 p.m. March 7, 2014 - Investors Business Daily
Insider Trading Alert - CNW, PPS And REGN Traded By Insiders 11:45 a.m. March 6, 2014 - TheStreet.com
10 Best Stocks Since the Bull Market Began 10:15 a.m. March 6, 2014 - InvestorPlace.com
Update on Bayer/Regeneron's Eylea - Analyst Blog 4:55 p.m. March 5, 2014 - Zacks.com
Regeneron Pharmaceuticals (REGN) Hits New Lifetime High Today 9:45 a.m. March 5, 2014 - TheStreet.com
Cramer's Mad Money - 5 Putin-Proof Sectors (3/4/14) 6:13 a.m. March 5, 2014 - Seeking Alpha
Jim Cramer's 'Mad Money' Recap: Stocks on Sale 8:08 p.m. March 4, 2014 - TheStreet.com
Regeneron Pharmaceuticals Inc. (REGN): Today's Featured Drugs Winner 5:00 p.m. March 3, 2014 - TheStreet.com
Regeneron announces regulatory submission in Japan 10:20 a.m. March 3, 2014 - Seeking Alpha
Bayer: Xarelto and Eylea to reach peak revenues in 5-6 years 7:37 a.m. Feb. 28, 2014 - Seeking Alpha
Regeneron Pipeline Could Be The Big Story In 2014 5:30 p.m. Feb. 27, 2014 - Investors Business Daily
Biotech Stock Roundup: Isis Soars on Positive Data, Onconova Falls - Analyst Blog 10:26 a.m. Feb. 26, 2014 - Zacks.com
Marketing Authorization Applications, Quarterly Dividends, Publication of Clinical Trial Data, Acquisitions, and Financial Results - Analyst Notes on Regeneron, Amgen, Sangamo, Alnylam, and Agios 9:08 a.m. March 11, 2014 - PR Newswire - PRF
Stock Price Updates, Appointment, and Financial Results - Analyst Notes on Regeneron, DENTSPLY, AMAG, Cadence, and ArthroCare 11:50 a.m. March 6, 2014 - PR Newswire - PRF
Bayer HealthCare and Regeneron Announce Regulatory Submission of EYLEA® (aflibercept) Injection for the Treatment of Diabetic Macular Edema in Japan 2:00 a.m. March 3, 2014 - PR Newswire - PRF
Critical Alerts For Walter Energy, Regeneron, Biogen Idec, Red Hat, and Level 3 Communications Released By InvestorsObserver 9:31 a.m. Feb. 27, 2014 - PR Newswire - PRF
Regeneron Announces FDA Acceptance of EYLEA® (aflibercept) Injection Supplemental Biologics License Application for the Treatment of Macular Edema Following Branch Retinal Vein Occlusion 7:30 a.m. Feb. 24, 2014 - PR Newswire - PRF
Regeneron Announces Upcoming 2014 Investor Conference Presentations 9:30 a.m. Feb. 14, 2014 - PR Newswire - PRF
Regeneron Reports Fourth Quarter and Full Year 2013 Financial and Operating Results 6:30 a.m. Feb. 11, 2014 - PR Newswire - PRF
Two-Year Results From Phase 3 VISTA Trial of EYLEA® (aflibercept) Injection for the Treatment of Diabetic Macular Edema Show Sustained Improvement in Vision 7:30 a.m. Feb. 10, 2014 - PR Newswire - PRF
Critical Alerts For Intel, Regeneron, Lowes, eBay, and KB Homes Released By InvestorsObserver 9:31 a.m. Jan. 23, 2014 - PR Newswire - PRF
Regeneron to Report Fourth Quarter and Full Year 2013 Financial and Operating Results and Host Conference Call and Webcast on February 11, 2014 9:30 a.m. Jan. 21, 2014 - PR Newswire - PRF
Regeneron and Bayer to Develop New Treatment Option for Wet Age-Related Macular Degeneration 4:05 p.m. Jan. 13, 2014 - PR Newswire - PRF
Regeneron and Geisinger Health System Announce Major Human Genetics Research Collaboration 8:00 a.m. Jan. 13, 2014 - PR Newswire - PRF
Regeneron Launches New Human Genetics Initiative 8:00 a.m. Jan. 13, 2014 - PR Newswire - PRF
Regeneron Announces Amendment to Investor Agreement with Sanofi 2:00 a.m. Jan. 13, 2014 - PR Newswire - PRF
Upcoming Presentations and Stock Price Movements - Research Report on Bard, Regeneron, Alexion, Seattle Genetics, and Isis Pharmaceuticals 8:00 a.m. Jan. 9, 2014 - PR Newswire
Clinical Study Updates, Collaborations, and Stock Price Updates - Research Report on Medtronic, Regeneron, Celldex, Cubist, and MannKind 8:00 a.m. Dec. 31, 2013 - PR Newswire
Critical Alerts For Stratasys, Regeneron, Ctrip, Paychex, and Tyson Released By InvestorsObserver 9:31 a.m. Dec. 23, 2013 - PR Newswire
Regulatory Updates, Clinical Trial Results, and Stock Price Movements - Research Report on Johnson & Johnson, Cubist, Regeneron, Medtronic, and Jazz Pharmaceuticals 8:00 a.m. Dec. 19, 2013 - PR Newswire
Sanofi and Regeneron Announce Collaboration with American College of Cardiology for PCSK9 Inhibitor Clinical Program 1:00 a.m. Dec. 19, 2013 - PR Newswire
Regeneron Announces FDA Acceptance of EYLEA® (aflibercept) Injection Supplemental Biologics License Application for Review for Diabetic Macular Edema Indication 7:30 a.m. Dec. 18, 2013 - PR Newswire
Nasdaq falls for 4th day in row; Dow, S&P slip for 2nd day: stock market live blog recap 3:51 p.m. March 11, 2014 - blogs.marketwatch.com
Bull market’s biggest winners and losers 7:00 a.m. March 10, 2014 - Jeff Reeves
Lorillard and Reynolds jump on buyout report 5:16 p.m. March 3, 2014 - Sue Chang
Sprint gains on narrower loss; WPX tops S&P 500 losers 5:15 p.m. Feb. 11, 2014 - Sue Chang
Dow nabs best gain of year after Yellen remarks, debt-ceiling news: stock market live blog recap 4:55 p.m. Feb. 11, 2014 - blogs.marketwatch.com
Regeneron diabetic eye remedy does well in trial 9:02 a.m. Feb. 10, 2014 - MarketWatch.com
Stocks stabilize; now it’s up to Yellen, the consumer 9:01 a.m. Feb. 9, 2014 - Wallace Witkowski
Tesla extends gains; ExOne sinks on revenue warning 4:45 p.m. Jan. 15, 2014 - Sue Chang
GameStop tumbles 20%; Tesla surges on strong sales 5:23 p.m. Jan. 14, 2014 - Sue Chang
Regeneron climbs by double-digits, leads S&P after presentation 4:58 p.m. Jan. 14, 2014 - Russ Britt
Dow jumps 116 points, best day this year: Stock market live blog recap 4:51 p.m. Jan. 14, 2014 - blogs.marketwatch.com
Three biopharma companies poised for product OKs in 2014: analyst 1:51 p.m. Jan. 6, 2014 - Russ Britt
Goldman's biotech downgrade and the new consensus 12:53 p.m. Jan. 6, 2014 - MarketWatch.com
Apple off on market data, Twitter down as options debut 5:36 p.m. Nov. 15, 2013 - Sue Chang
Macy's, Potbelly gain; Chegg slumps in debut 6:04 p.m. Nov. 13, 2013 - Sue Chang
GT spikes on sapphire deal with Apple 5:45 p.m. Nov. 5, 2013 - Sue Chang
Regeneron shares near $300 as earnings report emboldens investors 12:14 p.m. Nov. 5, 2013 - Russ Britt
The next big pharma 7:01 a.m. Oct. 25, 2013 - The Trading Deck
Apple extends gains on price target hike 3:47 p.m. Oct. 16, 2013 - Sue Chang
Apple gains on upgrade; BlackBerry rallies 4:34 p.m. Oct. 7, 2013 - Sue Chang
Piper Jaffray Stocks to Buy for S&P 500 Going to 2,100 8:00 a.m. March 13, 2014 - 247WallSt.com
Biotech Stock Roundup: Amgen, Regeneron Slide on PCSK9 Inhibitor Concerns - Analyst Blog 10:50 a.m. March 12, 2014 - Zacks.com
Next Stop for the Nasdaq: 5000 3:33 a.m. March 8, 2014 - Barrons.com
Jim Cramer's 'Mad Money' Recap: Next Week's Game Plan 8:17 p.m. March 7, 2014 - TheStreet.com
FDA Advises of Adverse Effects from New Cholesterol Drugs 6:08 p.m. March 7, 2014 - The Wall Street Journal Interactive Edition
Regeneron and Sanofi to look into side effects of cholesterol drug candidate 4:24 p.m. March 7, 2014 - Seeking Alpha
3 Stocks Reiterated As A Hold: FCX, TSLA, REGN 3:01 p.m. March 7, 2014 - TheStreet.com
Water-Logged And Getting Wetter: Regeneron Pharmaceuticals (REGN) 1:17 p.m. March 7, 2014 - TheStreet.com
Regeneron Cholesterol-Drug Worries Ding Stock 1:11 p.m. March 7, 2014 - Investors Business Daily
Insider Trading Alert - CNW, PPS And REGN Traded By Insiders 11:45 a.m. March 6, 2014 - TheStreet.com
10 Best Stocks Since the Bull Market Began 10:15 a.m. March 6, 2014 - InvestorPlace.com
Update on Bayer/Regeneron's Eylea - Analyst Blog 4:55 p.m. March 5, 2014 - Zacks.com
Regeneron Pharmaceuticals (REGN) Hits New Lifetime High Today 9:45 a.m. March 5, 2014 - TheStreet.com
Cramer's Mad Money - 5 Putin-Proof Sectors (3/4/14) 6:13 a.m. March 5, 2014 - Seeking Alpha
Jim Cramer's 'Mad Money' Recap: Stocks on Sale 8:08 p.m. March 4, 2014 - TheStreet.com
Regeneron Pharmaceuticals Inc. (REGN): Today's Featured Drugs Winner 5:00 p.m. March 3, 2014 - TheStreet.com
Regeneron announces regulatory submission in Japan 10:20 a.m. March 3, 2014 - Seeking Alpha
Bayer: Xarelto and Eylea to reach peak revenues in 5-6 years 7:37 a.m. Feb. 28, 2014 - Seeking Alpha
Regeneron Pipeline Could Be The Big Story In 2014 5:30 p.m. Feb. 27, 2014 - Investors Business Daily
Biotech Stock Roundup: Isis Soars on Positive Data, Onconova Falls - Analyst Blog 10:26 a.m. Feb. 26, 2014 - Zacks.com
Marketing Authorization Applications, Quarterly Dividends, Publication of Clinical Trial Data, Acquisitions, and Financial Results - Analyst Notes on Regeneron, Amgen, Sangamo, Alnylam, and Agios 9:08 a.m. March 11, 2014 - PR Newswire - PRF
Stock Price Updates, Appointment, and Financial Results - Analyst Notes on Regeneron, DENTSPLY, AMAG, Cadence, and ArthroCare 11:50 a.m. March 6, 2014 - PR Newswire - PRF
Bayer HealthCare and Regeneron Announce Regulatory Submission of EYLEA® (aflibercept) Injection for the Treatment of Diabetic Macular Edema in Japan 2:00 a.m. March 3, 2014 - PR Newswire - PRF
Critical Alerts For Walter Energy, Regeneron, Biogen Idec, Red Hat, and Level 3 Communications Released By InvestorsObserver 9:31 a.m. Feb. 27, 2014 - PR Newswire - PRF
Regeneron Announces FDA Acceptance of EYLEA® (aflibercept) Injection Supplemental Biologics License Application for the Treatment of Macular Edema Following Branch Retinal Vein Occlusion 7:30 a.m. Feb. 24, 2014 - PR Newswire - PRF
Regeneron Announces Upcoming 2014 Investor Conference Presentations 9:30 a.m. Feb. 14, 2014 - PR Newswire - PRF
Regeneron Reports Fourth Quarter and Full Year 2013 Financial and Operating Results 6:30 a.m. Feb. 11, 2014 - PR Newswire - PRF
Two-Year Results From Phase 3 VISTA Trial of EYLEA® (aflibercept) Injection for the Treatment of Diabetic Macular Edema Show Sustained Improvement in Vision 7:30 a.m. Feb. 10, 2014 - PR Newswire - PRF
Critical Alerts For Intel, Regeneron, Lowes, eBay, and KB Homes Released By InvestorsObserver 9:31 a.m. Jan. 23, 2014 - PR Newswire - PRF
Regeneron to Report Fourth Quarter and Full Year 2013 Financial and Operating Results and Host Conference Call and Webcast on February 11, 2014 9:30 a.m. Jan. 21, 2014 - PR Newswire - PRF
Regeneron and Bayer to Develop New Treatment Option for Wet Age-Related Macular Degeneration 4:05 p.m. Jan. 13, 2014 - PR Newswire - PRF
Regeneron and Geisinger Health System Announce Major Human Genetics Research Collaboration 8:00 a.m. Jan. 13, 2014 - PR Newswire - PRF
Regeneron Launches New Human Genetics Initiative 8:00 a.m. Jan. 13, 2014 - PR Newswire - PRF
Regeneron Announces Amendment to Investor Agreement with Sanofi 2:00 a.m. Jan. 13, 2014 - PR Newswire - PRF
Upcoming Presentations and Stock Price Movements - Research Report on Bard, Regeneron, Alexion, Seattle Genetics, and Isis Pharmaceuticals 8:00 a.m. Jan. 9, 2014 - PR Newswire
Clinical Study Updates, Collaborations, and Stock Price Updates - Research Report on Medtronic, Regeneron, Celldex, Cubist, and MannKind 8:00 a.m. Dec. 31, 2013 - PR Newswire
Critical Alerts For Stratasys, Regeneron, Ctrip, Paychex, and Tyson Released By InvestorsObserver 9:31 a.m. Dec. 23, 2013 - PR Newswire
Regulatory Updates, Clinical Trial Results, and Stock Price Movements - Research Report on Johnson & Johnson, Cubist, Regeneron, Medtronic, and Jazz Pharmaceuticals 8:00 a.m. Dec. 19, 2013 - PR Newswire
Sanofi and Regeneron Announce Collaboration with American College of Cardiology for PCSK9 Inhibitor Clinical Program 1:00 a.m. Dec. 19, 2013 - PR Newswire
Regeneron Announces FDA Acceptance of EYLEA® (aflibercept) Injection Supplemental Biologics License Application for Review for Diabetic Macular Edema Indication 7:30 a.m. Dec. 18, 2013 - PR Newswire
(0)
(0)